ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1904

Orphan Nuclear Receptor Rorα Is a Key Regulator of Tgfβ- and WNT-Signaling in Fibrotic Diseases

Rosebeth Kagwiria1, Ruifang Liang1, Alexandru Matei1, Niclas Sihler2, Chih-Wei Chen1, Thomas Burris3, Oliver Distler4, Georg Schett1 and Jörg Distler1, 1Friedrich-Alexander-University Erlangen-Nuremberg (FAU), Department of Internal Medicine 3 – Rheumatology and Immunology, University Hospital Erlangen, Erlangen, Germany, 2Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Department of Internal Medicine 3 – Rheumatology and Immunology, Universitätsklinikum Erlangen, Erlangen, Germany, 3Department of pharmacology and physiology, Saint Luis University-school of medicine, Florida, USA, St. Louis, Missouri, MO, 4Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Nuclear hormone receptor, systemic sclerosis and tissue growth factor (TGF), WNT Signaling

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, October 22, 2018

Title: 4M109 ACR Abstract: Systemic Sclerosis & Rel D/Os–Basic Science (1899–1904)

Session Type: ACR Concurrent Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose: The Retinoic-acid related Orphan Receptor-alpha (RORα) is a member of the nuclear receptor superfamily and a ligand-dependent transcription factor implicated in a wide range of physiological and pathological processes. Although individual key mediators of fibroblast activation such as TGFβ and WNT pathways have been identified, the factors that coordinate the activation and interaction of those pathways remain largely enigmatic. Here, we aim to evaluate the role of RORα in the pathogenesis of fibrotic diseases.

Methods: Mice carrying Rorαfl/flxCol1a2-CreER were generated to specifically knockout Rorα in fibroblasts in an inducible manner. RORα was inactivated using the selective inhibitor SR3335. The role of RORα was investigated in different mouse models: Bleomycin- and TBRICA -induced dermal fibrosis, bleomycin-induced pulmonary fibrosis, carbon tetrachloride (CCL4)-induced liver fibrosis and in Wnt-10b transgenic mice. The activity of TGFβ/SMAD signaling pathway was analyzed by reporter assays. RNA sequencing was performed to determine target genes of RORα in fibroblasts.

Results: The expression of RORα was upregulated in fibroblasts in both human and murine fibrotic lung and liver. Activation of canonical Wnt/β-catenin signaling mimicked the increase of RORα in fibrosis and potently induced RORα expression. Reporter assays showed that canonical Wnt ligands induced the transcriptional activity of RORα, which could be prevented by Wnt signaling antagonists Dickkopf. Inhibition of RORα signaling by incubation with SR3335 inhibited WNT- and TGFβ-dependent myofibroblast differentiation and effectively reduced the release of collagen. Reporter assay demonstrated that SR3335 dramatically inhibited TGFβ/SMAD signaling pathway activity. Knockout of RORα reduced the stimulatory effects of TGFβ and WNT on fibroblast activation and collagen release. In contrast, fibroblasts overexpressing RORα are more susceptible to the profibrotic effects of TGFβ and WNT. In addition, fibroblast-specific inactivation of RORα in vivo protected from experimental fibrosis induced by bleomycin injection. Furthermore, treatment with SR3335 effectively reduced Wnt-induced fibrosis in vivo. Dermal thickening, myofibroblast differentiation and hydroxyproline content were all significantly reduced in Wnt10b-tg mice treated with SR3335 as compared to vehicle-treated littermates. Inhibition of RORα also ameliorated TGFβ-dependent fibrosis with potent antifibrotic effects in mice overexpressing TBRICA. Treatment with SR3335 also reduced bleomycin-induced skin and lung fibrosis and CCL4-induced liver fibrosis.

Conclusion: The present study characterizes RORα as a key checkpoint of TGFβ- and WNT- induced fibroblast activation. RORα is induced in fibrotic diseases in a WNT-dependent manner to promote TGFβ- and WNT-induced fibroblast activation and tissue fibrosis. Targeting of RORα simultaneously interferes with TGFβ- and WNT-signaling as two core pathways in the pathogenesis of fibrotic diseases. The inhibition of those core pathways translates into potent antifibrotic effects across different models and organ systems.


Disclosure: R. Kagwiria, None; R. Liang, None; A. Matei, None; N. Sihler, None; C. W. Chen, None; T. Burris, None; O. Distler, None; G. Schett, None; J. Distler, 4DScience, 1, 4,Anamar, Active Biotech, Array Biopharma, aTyr, BMS, Bayer Pharma, Boehringer Ingelheim, Celgene, Galapagos, GSK, Inventiva, Novartis, Sanofi-Aventis, RedX, UCB, 2,Actelion, Active Biotech, Anamar, Bayer Pharma, Boehringer Ingelheim, Celgene, Galapagos, GSK, Inventiva, JB Therapeutics, Medac, Pfizer, RuiYi and UCB, 8.

To cite this abstract in AMA style:

Kagwiria R, Liang R, Matei A, Sihler N, Chen CW, Burris T, Distler O, Schett G, Distler J. Orphan Nuclear Receptor Rorα Is a Key Regulator of Tgfβ- and WNT-Signaling in Fibrotic Diseases [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/orphan-nuclear-receptor-ror%ce%b1-is-a-key-regulator-of-tgf%ce%b2-and-wnt-signaling-in-fibrotic-diseases/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/orphan-nuclear-receptor-ror%ce%b1-is-a-key-regulator-of-tgf%ce%b2-and-wnt-signaling-in-fibrotic-diseases/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology